vimarsana.com

Latest Breaking News On - Inserm magendie neurocentre - Page 1 : vimarsana.com

Aelis Farma: Ordinary General Meeting of June 28, 2022: Availability of Preparatory Documents and Participation and Voting Procedures

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),

United statesNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaAlbert marquetInserm transfert initiativeCentre broca nouvelle aquitaineNeurology of the french academy sciencesRegulatory newsOrdinary general meetingGeneral meetingInvestors generalCommercial codeSignaling specificPier vincenzo piazza

Aelis Farma: Ordinary General Meeting of June 28, 2022: Availability of Preparatory Documents and Pa

BORDEAUX, France (BUSINESS WIRE) Regulatory News:Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), informs its shareholders and the financial community that the Company’s Ordinary Gene.

United statesNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaAlbert marquetInserm transfert initiativeCentre broca nouvelle aquitaineNeurology of the french academy sciencesRegulatory newsOrdinary general meetingGeneral meetingCommercial codeSignaling specificPier vincenzo piazzaGrand prix

AELIS FARMA: Aelis Farma: Publication of the 2021 Annual Financial Report

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the

United statesFrance generalNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaInserm transfert initiativeFrench financial markets authority autoritNeurology of the french academy sciencesRegulatory newsFrench financial markets authoritySignaling specificPier vincenzo piazzaGrand prixFrench academyNouvelle aquitaine region

ODDO BHF Initiates the Coverage of Aelis Farma With a Buy Recommendation

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),

United statesNicolas merigeauVincenzo piazzaInserm magendie neurocentreDaelis farmaInserm transfert initiativeNeurology of the french academy sciencesRegulatory newsGeneral meetingSignaling specificPier vincenzo piazzaGrand prixFrench academyNouvelle aquitaine regionMarine de fages

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

16.02.2022 - Regulatory News: Aelis Farma (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the Company ), announces today the successful completion of its initial public offering on .

United statesUnited kingdomBpifrance financementVincenzo piazzaInserm magendie neurocentreDaelis farmaIndivior united kingdom ltdInserm transfert initiativeEuropean parliamentUnited kingdom financial conduct authorityNeurology of the french academy sciencesFinancial servicesEuropean union withdrawalCommission delegated directiveInnovative companySignaling specific

vimarsana © 2020. All Rights Reserved.